摘要
【目的】探讨孟鲁司特对小儿变应性紫癜（HSP）患者治疗前后白细胞介素6（IL-6）、白细胞介素-12（IL-12）的影响及其临床疗效。【方法】100例HSP患儿随机分为试验组和对照组，每组50例，对照组采用常规治疗方案，试验组在常规治疗的基础上加上孟鲁司特治疗，两组的治疗周期均为3周。比较两纽治疗前后IL-6、IL-12的变化情况，同时观察并比较两组的临床疗效。【结果】治疗后，试验组和对照组患儿血清细胞因子IL-6、IL-12水平均较治疗前明显下降，且差异均有显著性（P〈0．01）；试验组IL-6、IL-12水平明显低于对照组，且差异均有显著性（P〈0．05）；试验组治疗总有效率（96．0％）明显高于对照组（76．0％），皮疹消退时间（5．8±1．2d）、腹痛缓解时间（11．5±1．6d）和关节肿痛消退时间（12．8±4．2d）均明显优于照组，且差异均有显著性（P〈0．05）。【结论】在常规治疗基础上辅以盂鲁司特治疗小儿HSP能明显降低IL-6、IL-12水平，患儿总有效率及临床症状改善时间方面优于常规治疗。
[Objective] To explore the effects of montelukast on interleukin-6 （IL-6） and interleukin-12 （IL-12） in patients with Henoch-Sehonlein purpura （HSP） and its clinical efficacy. [Methods] A total of 100 HSP children were randomly divided into experimental and control groups （n= 50 each）. The control group received conventional treatment while the experimental group had additional montelukast. After 3-week treatment, the changes of IL-6 and IL-12 before and after treatment were compared for two groups. Also clinical efficacy, rash resolving time, abdominal pain and joint swelling resolving time were analyzed. [Results] After treatment, the serum levels of IL-6 and IL-12 levels declined markedly in both groups. However there was a larger decline in experimental group and the inter-group differences were statistically significant （P〈0.05）. The symptoms improved in both groups. The overall efficacy of experimental group was significantly higher than that of control group （96.0% vs 76.0%, P 〈0.05）. And the resolving times of rash, abdominal pain and joint swelling were shorter in experimental group than those in control group （ P 〈0.05）. And no adverse reactions occurred during treatment in neither group. [Conclusion] A combination of conventional treatment and montelukast is both safe and efficacious for HSP children. And improvements of overall efficacy and clinical symptoms may be mediated by a down-regulation of IL-6 and IL-12.
出处
《医学临床研究》
CAS
2015年第7期1293-1295,共3页
Journal of Clinical Research
